Prognosis of incidental pulmonary embolism vs. symptomatic pulmonary embolism in cancer patients: a single-center retrospective cohort study in China

Table 3 Treatment of PE and Effect of PE on anti-cancer treatment

	IPE, N = 88	SPE, N = 92	P-value
	N = 83	N = 91
Anticoagulation	81 (97.6)	90 (98.9)	0.465
	N = 78	N = 90
Initial anticoagulant treatment
LMWH	61 (78.2)	80 (88.9)	0.004^*
Unfractionated heparin	0 (0.0)	2 (2.2)	0.260
Warfarin	9 (11.5)	6 (6.7)	0.369
Rivaroxaban	8 (10.3)	2 (2.2)	0.043*
Whole anticoagulation course
LMWH	65 (83.3)	79 (87.8)	0.044^*
Unfractionated heparin	0 (0.0)	3 (3.3)	0.131
Warfarin	12 (15.4)	14 (15.6)	0.933
Rivaroxaban	13 (16.7)	9 (10.0)	0.307
	N = 88	N = 92
IVC filter placement	9 (10.2)	6 (6.5)	0.356
Thrombolytic therapy	2 (2.3)	3 (3.3)	0.521
	N = 66	N = 73
Standard dosage of LMWH	46 (69.7)	54 (74.0)	0.706

Data are presented as n (%)
IPE, incidental pulmonary embolism; SPE, symptomatic pulmonary embolism; PE, pulmonary embolism; LMWH, low molecular weight heparin; IVC, inferior vena cava; * means P < 0.05

ISSN: 1477-9560